ZOCOR Drug Patent Profile

Which patents cover Zocor, and when can generic versions of Zocor launch?

Zocor is a drug marketed by Organon and is included in one NDA.

The generic ingredient in ZOCOR is simvastatin. There are forty drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the simvastatin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zocor

A generic version of ZOCOR was approved as simvastatin by AUROBINDO PHARMA on December 20^th, 2006.

Summary for ZOCOR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	113
Drug Prices:	Drug price information for ZOCOR
What excipients (inactive ingredients) are in ZOCOR?	ZOCOR excipients list
DailyMed Link:	ZOCOR at DailyMed

See drug prices for ZOCOR

See drug sales revenues for ZOCOR

Pharmacology for ZOCOR

Drug Class	HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors

US Patents and Regulatory Information for ZOCOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	ZOCOR	simvastatin	TABLET;ORAL	019766-001	Dec 23, 1991	AB	RX	Yes	No
Organon	ZOCOR	simvastatin	TABLET;ORAL	019766-004	Dec 23, 1991	AB	RX	Yes	No
Organon	ZOCOR	simvastatin	TABLET;ORAL	019766-002	Dec 23, 1991	AB	RX	Yes	No
Organon	ZOCOR	simvastatin	TABLET;ORAL	019766-003	Dec 23, 1991	AB	RX	Yes	No

International Patents for ZOCOR

See the table below for patents covering ZOCOR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	16704
Australia	548996
Australia	6657381
Bulgaria	61418

Supplementary Protection Certificates for ZOCOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0033538	SPC/GB93/005	United Kingdom
0720599	SPC/GB05/010	United Kingdom		PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411
0720599	05C0040	France		PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402
0720599	26/2005	Austria		PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402

Zocor (simvastatin) Market Dynamics and Financial Trajectory (U.S. and Key International Markets)

Last updated: July 29, 2026

Zocor is a legacy statin with a mature, generic-dominated market. In the U.S., the product is economically constrained by generic competition and the class’s ongoing demand shift toward higher-potency branded statins and branded add-ons in downstream therapy settings. Internationally, the pace of generic penetration and pricing controls determine the remaining brand revenue base.

When did Zocor lose exclusivity, and what does that mean for current market dynamics?

Answer: Zocor’s market exclusivity ended years ago, and the U.S. market is now overwhelmingly generic. Residual brand share depends on contracting behavior, formulary placement, and switch friction rather than regulatory exclusivity.

How the generic lifecycle shapes price and volume

• U.S. genericization effect: Once multiple generic entrants are established, pricing typically compresses quickly and continues to ratchet down based on competition and pharmacy benefit manager (PBM) bidding.
• Brand-to-generic substitution: Statins have high interchangeability and long-standing clinical familiarity, which accelerates switching after exclusivity loss.
• Trade-down limits: Even when a payer requires “simvastatin,” it usually permits lowest-cost generics, shrinking pricing power for the brand.

What is the current competitive unit economics reality?

• Pricing is determined by lowest net cost, not branded premium.
• Volume is driven by formulary tiers, copay design, and prior authorization for alternatives rather than by brand advertising.

What is the current financial trajectory for Zocor, and which KPIs matter most?

Answer: The brand’s financial trajectory is defined by declining brand revenue and persistent generic share gains. The main KPIs are brand net sales, generic price indices, formulary placement, and prescription share across statin subclasses.

Core business drivers

• Formulary mix by statin intensity: Patients moving to high-potency regimens (or to statin plus non-statin therapies) reduce relative Zocor exposure.
• Consolidation of supply chains: Generic manufacturers with scale improve pricing resilience, which pressures remaining branded economics.
• PBM contracting structure: Zocor revenue performance tracks PBM rebate and tiering competitiveness rather than demand growth alone.

Observable market pattern for mature statins

• Brand revenue base shrinks as biosimilar-style dynamics do not apply, but generic substitution does.
• Category volume can grow due to guideline adherence, screening, and expanded indications, but brand share generally declines faster than category volume rises.

How do generic simvastatin and other statins compete with Zocor?

Answer: Zocor competes on price versus multiple generic simvastatin products and on comparative efficacy versus other statins and downstream combination therapies.

How substitution works in practice

• Therapeutic equivalence: Simvastatin is a standard statin, making substitution clinically routine.
• Dose switching: Many prescribers can adjust dose within the same active ingredient class if potency needs change.
• Payer controls: Step edits can restrict brand use, and prior authorization can steer patients toward preferred generics or preferred statins.

Key category competitors

• Other statins: atorvastatin, rosuvastatin (more commonly positioned for higher-intensity therapy).
• Adjuncts and add-ons: ezetimibe-based strategies and newer lipid-lowering agents in high-risk patients, depending on coverage policies.

What are the main market dynamics in the U.S. for Zocor?

Answer: The U.S. market is shaped by generic simvastatin penetration, PBM contracting, and high substitution rates within the statin class.

PBM and payer incentives that suppress branded simvastatin

• Preferred lists typically favor lowest net cost generics.
• Step edits and formulary tiering usually reduce brand access unless brand pricing and rebates remain competitive.
• Even if brand remains on formularies, patient out-of-pocket exposure and copay support typically matter less than payer net cost.

Retail and institutional channels

• Retail: High substitution with pharmacy dispensing data reflecting lowest-cost availability.
• Institutional: Pharmacy and therapeutics committees drive formulary selection, typically favoring generic stock.

How does Zocor’s international pricing and generic entry compare with the U.S.?

Answer: International financial trajectory depends on the timing of generic launches, local price controls, and reimbursement systems. The brand’s remaining economic value generally declines as generics gain coverage and tendering awards.

What international levers most affect Zocor revenue

• Reference pricing and mandated cost containment.
• Tendering in public systems where generic supply and bid pricing determine utilization.
• Reimbursement restrictions that steer patients to preferred generics or other statins.

Where brands can persist longer

• Markets with slower generic adoption, limited tendering flexibility, or continued brand availability in specific reimbursement pathways.

What is the financial trajectory risk from new lipid-lowering treatment patterns?

Answer: The key risk is not patent cliff dynamics, but clinical pathway shifts that reduce reliance on simvastatin monotherapy and increase utilization of other regimens in high-risk patients.

Pathway shifts that reduce Zocor share

• Increased use of high-intensity statin strategies (commonly atorvastatin or rosuvastatin).
• Broader adoption of statin add-on approaches for patients not reaching LDL-C targets.
• Coverage-driven selection of preferred agents.

How many brands versus generics exist for simvastatin, and how does that translate into pricing pressure?

Answer: Zocor faces dense generic competition across multiple strengths and dosage forms, which usually produces rapid margin compression.

Pricing pressure mechanics

• Multiple generic entrants increase competitive intensity.
• PBMs and wholesalers exert downward pressure through bidding and contracting.
• Small pricing differences at the unit level translate into large budget impact for payers and channels with scale purchasing.

What does the revenue trajectory imply for Zocor’s commercial future?

Answer: Zocor’s future is primarily a legacy brand with limited upside. Commercial outcomes are largely determined by payer contracting and the durability of generic pricing rather than by demand growth for branded simvastatin.

Practical scenario drivers

• Brand net pricing and rebate competitiveness can sustain small revenue but rarely reverse long-term decline.
• Generic pricing volatility can change absolute economics, but it does not restore brand exclusivity.
• Switching friction can delay substitution in specific physician segments, but category-level dynamics dominate.

How does Zocor compare with other statins on market momentum?

Answer: Other statins have structurally stronger market positions when they align with high-intensity guideline framing or preferred formulary status, while Zocor is constrained by generic substitution.

Comparison dimensions that matter financially

• Formulary preference as “first-line” or “preferred statin.”
• Strength of contracting and PBM incentives.
• Use pattern for intensification and LDL-C target attainment.

What does Zocor’s patent estate and litigation posture mean for financial planning now?

Answer: For financial planning, the relevant reality is that exclusivity has already ended and market structure is generic-dominated, so the incremental financial risk from patent events is low compared with category-level substitution dynamics.

Why patent events rarely change the current market structure

• Generic competition is already established.
• Any remaining brand economics depend on contracting and pricing, not on exclusivity renewal.

Key takeaways

• Zocor’s financial trajectory is a legacy-brand decline model driven by generic simvastatin dominance in the U.S. and competitive tendering and reference pricing abroad.
• The dominant market dynamics are PBM contracting, formularies, and high substitution rates within the statin class, not exclusivity.
• Financial direction is primarily shaped by category treatment pattern shifts that move high-risk patients toward other statins and add-on regimens.
• Near- to medium-term commercial outcomes are limited upside and depend on net pricing/rebate strategy and the stability of generic pricing rather than on patent-driven barriers.

FAQs

1. Why does branded simvastatin revenue continue to decline after generic entry?
2. Do payers prefer simvastatin over other statins, and how does that impact Zocor?
3. How do PBM rebates and formulary tiering affect Zocor net sales?
4. What clinical guideline changes most influence long-term simvastatin market share?
5. How does international reference pricing change Zocor’s profit trajectory versus the U.S.?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. IQVIA Institute / IQVIA. U.S. and global pharmaceutical market trends (statins and generics reporting).
3. Wolters Kluwer (Lexicomp or similar). Statin clinical coverage and dosing/intensity frameworks.

DrugChatter Q&A for ZOCOR

Can you rank zocor side effects from worst to least bothersome?
What prompted the move from zocor to lipitor?
Which specific side effects made zocor intolerable?
Are you considering switching from zocor to lipitor?
What concerns prompted considering a switch from zocor to lipitor?